UM school of medicine surgeon-scientists to co-lead large international clinical trial to determine most effective treatment for common hip fracture in older adults
THT 2025 Late-Breaking Clinical Science Unveiled
A nasal vaccine for COVID-19 鈥� based on technology developed at Washington University in St. Louis 鈥� is poised to enter a phase 1 clinical trial in the U.S.
Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for children with B-cell acute lymphoblastic leukemia (ALL). But unfortunately, CAR T-cells have been far less effective for another blood cancer: acute myeloid leukemia (AML).
The first participants in an international clinical trial aimed at preventing Alzheimer鈥檚 disease in young adults at high risk of the disease have been enrolled. The trial, led by Washington University School of Medicine in St. Louis, aims to determine whether stopping the early molecular changes that lead to symptomatic Alzheimer鈥檚 disease can prevent the disease from ever taking hold.
NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, announced it has received approval for its Phase 2 clinical trial from the European Medicines Agency (EMA). NTRX-07, the Company's lead molecule, will be administered to Alzheimer's disease (AD) participants for 28 days in this double-masked, randomized clinical trial.
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.
Pesquisadores da Mayo Clinic identificaram uma terapia direcionada que pode trazer al铆vio para as pessoas que vivem com l铆quen plano, uma condi莽茫o inflamat贸ria cr么nica da pele, cabelo, unhas, boca e genitais. Eles descreveram suas descobertas em um estudo publicado no Journal of Clinical Investigation, relatando seu primeiro ensaio cl铆nico em humanos, fase 2.
Investigadores de Mayo Clinic han identificado una terapia dirigida que puede brindar alivio a las personas que viven con liquen plano, una condici贸n inflamatoria cr贸nica de la piel, cabello, u帽as, boca y genitales. Ellos escribieron sus hallazgos en un estudio publicado en el Journal of Clinical Investigation, informando su primer ensayo cl铆nico en humanos, fase 2.
Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a chronic inflammatory skin condition of the skin, hair, nails, mouth and genitals. They described their findings in a study published in the Journal of Clinical Investigation that described their first-in-human, phase 2 clinical trial.
For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week. Currently, patients are treated with injections of asfotase alfa, a mineral-targeted form of the missing enzyme called tissue-nonspecific alkaline phosphatase (TNAP). This FDA-approved therapy is based on a Sanford Burnham Prebys scientist鈥檚 decades of research on the TNAP enzyme and his laboratory鈥檚 studies demonstrating preclinical safety and efficacy. In a paper published January 12, 2025, in鈥痶he Journal of Bone and Mineral Research, researchers added additional weight to prior preclinical evidence of the safety and effectiveness of a gene therapy for HPP.
January is Cervical Cancer Awareness Month, so it鈥檚 the perfect time to review facts about cervical cancer, HPV-associated risks, and screening recommendations. We鈥檒l also look at self-collected tests that have recently sparked interest.
Susan M. Domchek, MD, FASCO, has been recognized by the American Society of Clinical Oncology (ASCO) with one of the society鈥檚 highest honors, as the 2025 recipient of the ASCO-American Cancer Society Cancer Prevention Award.
A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes similar to the current standard of care, a clinical trial co-led by a UT Southwestern Medical Center researcher shows. The findings, published in the Journal of Clinical Oncology, could lead to new treatment regimens that are significantly safer and less detrimental to patients鈥� quality of life.
Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and room for improvement when it comes to treatment.Cutaneous lupus erythematosus is a common manifestation of systemic lupus erythematosus.The condition is characterized by rashes on various parts of the body including the face and scalp, hair loss and scarring of the skin.
Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a definitive agreement to acquire Evergreen Theragnostics, Inc. ("Evergreen"), in an all-cash transaction consisting of an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments.
The Miami Project to Cure Paralysis and the Department of Neurological Surgery at the University of Miami (UM) Miller School of Medicine have been selected to become the second U.S.-based site for Neuralink鈥檚 PRIME Study, an investigational medical device clinical trial for Neuralink鈥檚 ground-breaking brain-computer interface.
A clinical trial from Keck Medicine of USC aims to provide a surgical solution for patients with a form of advanced pancreatic cancer previously considered inoperable.
Loyola Medicine has been named to Becker's Hospital Review's 2024 list of 100 Great Neuro and Spine Programs.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 海角社区 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
